We propose a modest administrative core to oversee the management of the TMEN program. The central administration of the Koch Institute provides Grants and Financial Management, Accounting and Human Resources services so those are not included. Part-time services of an Administrative Assistant are requested to cover necessary administration specific to the program including arranging internal meetings, organizing External Scientific Advisory Board meetings and seminar visitors, including scheduling, and arranging travel, lodging and reimbursement. The AA will also act as intermediary with the central TMEN administration at NCI, preparing progress reports, arranging Principal Investigator/Project Directors (PI/PD) and trainee attendance at TMEN meetings , including scheduling, and arranging travel, lodging and reimbursement.. The AA, Ms. Isadora Deese, will report to the PI, Dr. Hynes, and is located in the same office suite as the PI in the Koch Institute, 1-2 floors away from the central administrative offices and from the laboratory of PD Tyler Jacks, ensuring ease of interaction. We do not propose a more formal administrative structure since the PI and other PDs are all located in close proximity (Koch and Whitehead face each other across the street and MGH is a short walk or a single subway stop away) and meetings are readily arranged as needed. The budgetary structure is simple - each project has Its own budget, two of them funded as contracts to Wl and to MGH and are separately administered within those institutions. Overall monitoring of the budget and financial reporting will be the responsibility of the PI, with assistance from the AA and the Finance Office at the Koch Institute

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA163109-04
Application #
8705471
Study Section
Special Emphasis Panel (ZCA1-SRLB-3)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
4
Fiscal Year
2014
Total Cost
$55,417
Indirect Cost
$14,296
Name
Massachusetts Institute of Technology
Department
Type
DUNS #
001425594
City
Cambridge
State
MA
Country
United States
Zip Code
02139
Kulkarni, Madhura; Tan, Tuan Zea; Syed Sulaiman, Nurfarhanah Bte et al. (2018) RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer. Oncotarget 9:14175-14192
Engblom, Camilla; Pfirschke, Christina; Zilionis, Rapolas et al. (2017) Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science 358:
Naba, Alexandra; Clauser, Karl R; Mani, D R et al. (2017) Quantitative proteomic profiling of the extracellular matrix of pancreatic islets during the angiogenic switch and insulinoma progression. Sci Rep 7:40495
Kwan, Byron H; Zhu, Eric F; Tzeng, Alice et al. (2017) Integrin-targeted cancer immunotherapy elicits protective adaptive immune responses. J Exp Med 214:1679-1690
Li, Ran; Hebert, Jess D; Lee, Tara A et al. (2017) Macrophage-Secreted TNF? and TGF?1 Influence Migration Speed and Persistence of Cancer Cells in 3D Tissue Culture via Independent Pathways. Cancer Res 77:279-290
Gocheva, Vasilena; Naba, Alexandra; Bhutkar, Arjun et al. (2017) Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A 114:E5625-E5634
Roper, Jatin; Tammela, Tuomas; Cetinbas, Naniye Malli et al. (2017) In vivo genome editing and organoid transplantation models of colorectal cancer and metastasis. Nat Biotechnol 35:569-576
Carmona, G; Perera, U; Gillett, C et al. (2016) Lamellipodin promotes invasive 3D cancer cell migration via regulated interactions with Ena/VASP and SCAR/WAVE. Oncogene 35:5155-69
Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen et al. (2016) Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. Immunity 44:343-54
De Cock, Jasmine M; Shibue, Tsukasa; Dongre, Anushka et al. (2016) Inflammation Triggers Zeb1-Dependent Escape from Tumor Latency. Cancer Res 76:6778-6784

Showing the most recent 10 out of 31 publications